Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens

Published: 08-05-2009
Last updated: 06-05-2024

The primary purpose of the study is to determine the efficacy of AZD2281 compared to placebo in serous ovariancancer platinum sensitive patients and in a defined HRD subset.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Reproductive neoplasms female malignant and unspecified
Study type	Interventional

Summary

ID

NL-OMON43643

Source
ToetsingOnline

Brief title
platinum sensitive serous ovarian cancer

Condition

- Reproductive neoplasms female malignant and unspecified

Synonym
cancer of the ovaries

Research involving
Human

Sponsors and support

Primary sponsor: Astra Zeneca
Source(s) of monetary or material Support: Astra Zeneca

Intervention

Keyword: ovarian cancer, Phase II, platinum sensitive

Outcome measures

Primary outcome

PFS as evaluated by RECIST

Secondary outcome

Efficacy: OS, best overall response, duration of response, CA-125 response

(GCIG criteria), time to progression by CA-125 (GCIG criteria) or RECIST,

Quality of Life (QoL) and disease related symptoms.

Measurement of candidate biomarkers (including but not limited to ATM,

MRE-11, MDC1, BRCA1/2) to identify the Homologous Recombination

Deficient subset of tumours for correlation with benefit/risk of treatment with

AZD2281.

Safety: AEs, physical examination, vital signs including BP, pulse, ECG and

laboratory findings including clinical chemistry, haematology and urinalysis.

Study description

Background summary

AZD2281 monotherapy has demonstrated significant anti-tumour activity, (while

being well
tolerated) for ovarian cancer patients (previously treated with platinum agents) harbouring
mutations in BRCA1 or BRCA2 (AstraZeneca, unpublished data). Many studies have indicated BRCA1/2 mutations and other BRCA1/2 defects are predominantly found within the
serous subset of ovarian cancer patients. It is therefore hypothesised that AZD2281 will have
significant anticancer activity in a large proportion of serous ovarian cancer patients. Please see page 25 of the study protocol

Study objective

The primary purpose of the study is to determine the efficacy of AZD2281 compared to placebo in serous ovarian
cancer platinum sensitive patients and in a defined HRD subset.

Study design

The study is a randomised, double blind, multi-centre study in platinum sensitive serous
ovarian cancer patients who have received 2 or more previous platinum containing regimens.
Platinum sensitivity is defined as disease progression greater than 6 months after completion
of their penultimate platinum regimen (from last dose) prior to enrolling on this study. In the
last platinum regimen prior to enrolling on this study, patients must have demonstrated an
objective stable maintained response (complete, or partial response by GCIG and/or RECIST)
and this response needs to be maintained to allow entry to the study.
The two platinum regimens do not necessarily have to be sequential.

Patients will be randomised within 8 weeks after their last dose of the platinum containing
regimen. Randomisation will be stratified by time to disease progression (>6-12 months and
>12 months, in the penultimate platinum therapy prior to enrolment), objective response (CR
or PR, in the last platinum therapy prior to enrolment) and whether a patient is of Jewish
descent (yes or no).

Intervention

Patients will be randomised in a 1:1 ratio (AZD2281:matching placebo) to one of 2 arms:
1. AZD2281 400mg bid
2. AZD2281 matching placebo bid

Study burden and risks

* Burden: Patiens will be asked to come to the site 14 times during the first 6 months.
Screening 2 - 2.5h = 30 minutes physical exam + anamnesis + Lab 30 min + 30 min CT + 30 min ECG + 30 min QoL
2nd Screening (if indicated) = Lab 15 min
First 8 weeks (2 cycles)= once a week - 30 minutes per visit
Every month / every two months - 1h visit
Expected duration study from previous clinical experience: 6-12 months, until disease progression

Total patient visit time based on expected study duration: 10-16h

* Risks are the possible side-effects of the study medication and risks associated with the study procedures like blood draws, CT- or MRI-scans and ECG. The side effects most commonly associated with AZD2281 are: anaemia, neutropenia and thrombocytopenia, nausea, vomiting and fatigue.

Contacts

Public
Astra Zeneca

Alderley Park, Macclesfield -
Parksland, Cheshire SE1 K/1
GB
Scientific
Astra Zeneca

Alderley Park, Macclesfield -
Parksland, Cheshire SE1 K/1
GB

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

1. Provision of voluntary obtained informed consent prior to any study specific procedures.
2. Female patients, > 18 years of age, with histologically diagnosed serous ovarian cancer or recurrent serous ovarian cancer with a histology type of serous, or a serous component and who have completed at least 2 previous courses of platinum containing therapy (e.g. carboplatin or cisplatin)
3. Formalin fixed, paraffin embedded tumour sample from the cancer must be available for central testing.

Exclusion criteria

1. Patients with low grade ovarian carcinoma.
2. Patients who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen prior to enrolment on the study.
3. Previous treatment with PARP inhibitors including AZD2281.

Study design

Design

Study phase:	2
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	15-10-2009
Enrollment:	8
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	nog niet bekend
Generic name:	olaparib

Ethics review

Approved WMO Date:	08-05-2009
Application type:	First submission
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	23-07-2009
Application type:	First submission
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	14-10-2009
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	25-03-2010
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Approved WMO Date:	19-07-2010
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	14-03-2011
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	26-09-2011
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	16-01-2012
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	14-06-2012
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	27-12-2012
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	23-08-2013
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	09-01-2014
Application type:	Amendment

Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	21-01-2014
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	08-08-2014
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	23-03-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	15-04-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2008-003439-18-NL
ClinicalTrials.gov	NCT00753545
CCMO	NL27719.031.09